Testing effectiveness (Phase 2)Study completedNCT00528528
What this trial is testing
An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants
Who this might be right for
Chronic Hepatitis C
Tibotec BVBA 166